Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

Significant drug interactions in dermatology

Systemic drugs have been used widely in the treatment of many skin diseases. Although dermatologists are familiar with the guidelines of selecting appropriate patients and prescribing systemic drugs, their knowledge about the side effects and significant interactions of systemic drugs used in dermatology is more limited. So a short review on important drug interactions seems to be useful. Some ...

Update: clinically significant cytochrome P-450 drug interactions.

Recent technologies have resulted in an explosion of information concerning the cytochrome P-450 isoenzymes and increased awareness of life-threatening interactions with such commonly prescribed drugs as cisapride and some antihistamines. Knowledge of the substrates, inhibitors, and inducers of these enzymes assists in predicting clinically significant drug interactions. In addition to inhibiti...

Clinically important drug interactions.

Clinically Significant Drug-Drug Interactions Between Hepatitis C Virus and HIV Treatments.

The potential for drug-drug interactions is an important consideration in the treatment of HIV/hepatitis C virus (HCV) coinfection. Regimens for HCV genotype 1 infection are discussed in the context of an individual on stable antiretroviral therapy, to determine which HCV treatments may be initiated without requiring a change in antiretroviral regimen or an increase in monitoring for potential ...

Potentially significant versus clinically significant drug interactions: pomegranate juice as a case in point.

In vitro and in vivo laboratory data show that pomegranate juice consistently inhibits intestinal CYP2C9 and CYP3A4 enzymes. Pomegranate juice may therefore increase the bioavailability of drugs that are metabolized by these enzymes. However, studies in humans find that pomegranate juice does not increase exposure to either CYP2C9 or CYP3A4 substrates. These contradictory findings suggest that ...